Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
Condition(s):Relapsing Multiple SclerosisLast Updated:August 7, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsing Multiple SclerosisLast Updated:August 7, 2023Active, not recruiting
Condition(s):Relapsing Multiple SclerosisLast Updated:August 7, 2023Active, not recruiting
Condition(s):Relapsing Multiple SclerosisLast Updated:October 3, 2023Active, not recruiting
Condition(s):Relapsing Multiple SclerosisLast Updated:October 4, 2023Active, not recruiting
Condition(s):Relapsing Multiple SclerosisLast Updated:October 1, 2021Completed
Condition(s):Relapsing Multiple ScelrosisLast Updated:November 22, 2021Completed
Condition(s):Multiple SclerosisLast Updated:September 1, 2023Active, not recruiting
Condition(s):Healthy Elderly Subjects (Age ≥55 Years)Last Updated:November 2, 2016Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:February 29, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.